Drug Trial Radar · NCT06552234
Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Oct 1, 2024
Primary completion
Sep 2031
Study completion Sep 2031
Sponsor
- Lead sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur MerAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Groupe Francais De Pneumo-Cancerologie; Hospices Civils de Lyon
- First posted
- Aug 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ROS1 rearrangements are rare, accounting for only 1-2% of NSCLC cases, but have been associated with response to ROS1 inhibitors, such as crizotinib and entrectinib. However, many patients develop resistance to the tyrosine-kinase inhibitors (TKIs), creating a need for new treatments. Repotrectinib is a new-generation TKI designed against ROS1 or NTRK rearranged malignancies (Drilon 2018). Early phase clinical data support activity of repotrectinib in patients with NSCLC harboring such gene rearrangements (TRIDENT-1 study), but there are limited evidence in frail populations, such as poor performance status patients and/or elderly patients, who are classically excluded from clinical trials or underrepresented. The present study aims to assess the activity and tolerability of repotrectinib in frail (PS ≥2) and/or elderly patients with ROS1-rearranged advanced NSCLC.
Conditions
- NSCLC Stage IV
- NSCLC, Stage III
Interventions
RepotrectinibDrug
Repotrectinib 160 mg BID, until progression or unacceptable toxicity
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR) according to RECIST v1.1.Time frame: From the date of first treatment administration until the date of disease progression or death if patient died before progression) or the introduction of a new treatment, which ever occurs earlier, assessed up to 7 years
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
CHU Angers
Angers, France · Recruiting
CHU Bordeaux
Bordeaux, France · Recruiting
CHU Brest
Brest, France · Recruiting
Centre François Baclesse
Caen, France · Recruiting
CH Chambéry
Chambéry, France · Recruiting
Hôpitaux civils de Colmar
Colmar, France · Recruiting
CHI Créteil
Créteil, France · Recruiting
CHD Vendée
La Roche-sur-Yon, France · Recruiting
CHRU Lille
Lille, France · Recruiting
CHU Limoges
Limoges, France · Recruiting
Hospices Civils de Lyon
Lyon, France · Recruiting
CH Cornouaille
Quimper, France · Recruiting
CHU Rennes
Rennes, France · Recruiting
CHU Rouen
Rouen, France · Recruiting
Hôpital Foch
Suresnes, France · Recruiting
CHU Toulouse
Toulouse, France · Recruiting
Hôpitaux Nord-Ouest
Villefranche-sur-Saône, France · Recruiting
CH Aix-en-Provence
Aix-en-Provence, Bouches Du Rhône, France · Recruiting
AP-HM
Marseille, Bouches Du Rhône, France · Recruiting
HIA Sainte Anne
Toulon, Var, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.